Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03313778
Title Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors ModernaTX, Inc.

Advanced Solid Tumor

bladder urothelial carcinoma

colorectal cancer

esophagus adenocarcinoma


gastric adenocarcinoma

endometrial cancer

lung non-small cell carcinoma

lung small cell carcinoma

head and neck squamous cell carcinoma


mRNA-4157 + Pembrolizumab


Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of Arizona Recruiting Tucson Arizona 85721 United States Details
Florida Cancer Specialists Recruiting Sarasota Florida 34232 United States Details
H Lee Moffitt Cancer Center and Research Institute Not yet recruiting Tampa Florida 33612-9416 United States Details
Massachusetts General Hospital Recruiting Boston Massachusetts 02114 United States Details
John Theurer Cancer Center Completed Hackensack New Jersey 07601 United States Details
NYU Langone Recruiting New York New York 10016 United States Details
Duke Cancer Institute Recruiting Durham North Carolina 27710 United States Details
The Cleveland Clinic Foundation Recruiting Cleveland Ohio 44195-0001 United States Details
Providence Portland Medical Center Recruiting Portland Oregon 97213-2933 United States Details
Sarah Cannon Research Institute, Tennessee Oncology Recruiting Nashville Tennessee 37203 United States Details
*Shaded cells indicate that there was no data available from for the field